Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLSNASDAQ:INSMNASDAQ:LEGNNASDAQ:NKTRNASDAQ:TPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$17.99+0.9%$18.14$16.10▼$42.47$2.26B0.672.35 million shs891,120 shsINSMInsmed$98.50+0.3%$80.30$60.40▼$106.83$18.69B0.92.31 million shs1.76 million shsLEGNLegend Biotech$35.35-1.6%$32.53$27.34▼$60.87$6.50B0.191.37 million shs604,100 shsNKTRNektar Therapeutics$24.65-3.4%$12.71$6.48▼$37.38$305.83M0.94476,131 shs994,109 shsTPTXTurning Point Therapeutics$76.01$75.83$23.77▼$82.20$3.81B-0.181.14 million shs4,322 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals+0.93%-2.26%-4.44%-9.94%-49.21%INSMInsmed+0.26%-3.18%+34.78%+42.38%+58.87%LEGNLegend Biotech-1.56%+5.59%+24.34%+10.43%-23.00%NKTRNektar Therapeutics-3.45%-16.95%+119.26%+197.76%+26.41%TPTXTurning Point Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLSApellis Pharmaceuticals4.4471 of 5 stars4.31.00.04.42.02.50.6INSMInsmed4.1609 of 5 stars2.54.00.04.33.41.70.6LEGNLegend Biotech3.2781 of 5 stars4.51.00.00.03.11.70.6NKTRNektar Therapeutics4.6704 of 5 stars3.55.00.04.23.72.50.0TPTXTurning Point TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.62Moderate Buy$39.79121.24% UpsideINSMInsmed 3.00Buy$106.808.43% UpsideLEGNLegend Biotech 2.91Moderate Buy$72.60105.37% UpsideNKTRNektar Therapeutics 3.00Buy$84.17241.45% UpsideTPTXTurning Point Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INSM, LEGN, TPTX, NKTR, and APLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025APLSApellis PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $26.007/2/2025LEGNLegend BiotechUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.00 ➝ $54.006/24/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $100.006/24/2025NKTRNektar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$120.006/11/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $112.006/11/2025INSMInsmedMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.006/11/2025INSMInsmedRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.006/11/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.006/11/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.006/11/2025INSMInsmedBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$94.00 ➝ $109.006/11/2025INSMInsmedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$90.00 ➝ $120.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$781.37M2.89N/AN/A$1.84 per share9.77INSMInsmed$381.03M49.04N/AN/A$1.60 per share61.56LEGNLegend Biotech$627.24M10.36N/AN/A$5.70 per share6.20NKTRNektar Therapeutics$87.25M3.51N/AN/A$4.94 per share4.99TPTXTurning Point Therapeutics$30.83M123.46N/AN/A$15.84 per share4.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals-$197.88M-$1.79N/AN/AN/A-28.83%-99.19%-25.35%7/30/2025 (Estimated)INSMInsmed-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/8/2025 (Estimated)NKTRNektar Therapeutics-$118.96M-$9.60N/AN/AN/A-152.49%-329.54%-55.24%8/6/2025 (Estimated)TPTXTurning Point Therapeutics-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/ALatest INSM, LEGN, TPTX, NKTR, and APLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LEGNLegend Biotech-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million5/8/2025Q1 2025INSMInsmed-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million5/8/2025Q1 2025NKTRNektar Therapeutics-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 million5/7/2025Q1 2025APLSApellis Pharmaceuticals-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals2.764.083.62INSMInsmed11.385.865.44LEGNLegend Biotech0.305.205.07NKTRNektar TherapeuticsN/A3.243.24TPTXTurning Point TherapeuticsN/A16.8316.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%INSMInsmedN/ALEGNLegend Biotech70.89%NKTRNektar Therapeutics75.88%TPTXTurning Point Therapeutics90.33%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%INSMInsmed3.00%LEGNLegend Biotech0.02%NKTRNektar Therapeutics5.25%TPTXTurning Point Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770125.68 million117.51 millionOptionableINSMInsmed1,271189.71 million184.02 millionOptionableLEGNLegend Biotech2,609183.76 million183.73 millionOptionableNKTRNektar Therapeutics22012.41 million11.76 millionOptionableTPTXTurning Point Therapeutics25050.07 million45.77 millionNot OptionableINSM, LEGN, TPTX, NKTR, and APLS HeadlinesRecent News About These CompaniesTurning Point Therapeutics Inc (TPTX) - Investing.comJune 26, 2025 | investing.comBMS sets up Roche, Pfizer rivalry with Turning Point takeoverMay 20, 2025 | pharmaphorum.comPDigging Into Turning Point USA’s Role in the Trump 2024 Ground GameOctober 8, 2024 | talkingpointsmemo.comTTurning Point of Tampa Now In-Network with Blue Cross Blue Shield InsuranceSeptember 29, 2024 | markets.businessinsider.comDigital therapeutics at a turning point: What we heard at DTx EastSeptember 14, 2024 | pharmaphorum.comPPTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comTG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | seekingalpha.comViking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call TranscriptJuly 25, 2024 | seekingalpha.comGlass System in Turning Point ResidenceApril 2, 2024 | archdaily.comABid to remove prosecutors sets up turning point in Trump’s Georgia caseFebruary 19, 2024 | politico.comPTurning Point Brands Inc.February 17, 2024 | wsj.comAlzheimer’s: A Turning Point?February 12, 2024 | bbc.co.ukTurning Point Brands Inc (TPB)February 10, 2024 | investing.comCormorant Asset Management, LP's Net WorthFebruary 10, 2024 | benzinga.comSolving quadratic equations - EdexcelJanuary 15, 2024 | bbc.co.ukCOP15: A Turning Point for Investor Approaches to BiodiversityDecember 19, 2023 | morningstar.comMTurning Point USA: Are conservatives fighting back on campus?December 16, 2023 | bbc.comBBMS bet looking good as Augtyro approved in ROS1-positive NSCLCNovember 16, 2023 | thepharmaletter.comTPhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in bloodOctober 29, 2023 | ulster.ac.ukUA Turning Point for Japan-US Climate Cooperation?October 28, 2023 | thediplomat.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeRussell Rebalance: 3 Stocks Ready to Move HigherBy Chris Markoch | June 20, 2025View Russell Rebalance: 3 Stocks Ready to Move HigherBiotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsBy Nathan Reiff | June 30, 2025View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?INSM, LEGN, TPTX, NKTR, and APLS Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$17.98 +0.17 (+0.93%) Closing price 07/3/2025 03:48 PM EasternExtended Trading$17.93 -0.05 (-0.31%) As of 07/3/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Insmed NASDAQ:INSM$98.50 +0.26 (+0.26%) Closing price 07/3/2025 03:07 PM EasternExtended Trading$98.50 0.00 (0.00%) As of 07/3/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Legend Biotech NASDAQ:LEGN$35.35 -0.56 (-1.56%) Closing price 07/3/2025 02:47 PM EasternExtended Trading$35.35 0.00 (0.00%) As of 07/3/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Nektar Therapeutics NASDAQ:NKTR$24.65 -0.88 (-3.45%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$24.72 +0.08 (+0.30%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Turning Point Therapeutics NASDAQ:TPTXTurning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.